189 related articles for article (PubMed ID: 21216927)
1. Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2.
Rizzo S; Hersey JM; Mellor P; Dai W; Santos-Silva A; Liber D; Luk L; Titley I; Carden CP; Box G; Hudson DL; Kaye SB; Brown R
Mol Cancer Ther; 2011 Feb; 10(2):325-35. PubMed ID: 21216927
[TBL] [Abstract][Full Text] [Related]
2. siRNA treatment targeting integrin α11 overexpressed via EZH2-driven axis inhibits drug-resistant breast cancer progression.
Chaudhary P; Yadav K; Lee HJ; Kang KW; Mo J; Kim JA
Breast Cancer Res; 2024 Apr; 26(1):72. PubMed ID: 38664825
[TBL] [Abstract][Full Text] [Related]
3. Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker.
Takawa M; Masuda K; Kunizaki M; Daigo Y; Takagi K; Iwai Y; Cho HS; Toyokawa G; Yamane Y; Maejima K; Field HI; Kobayashi T; Akasu T; Sugiyama M; Tsuchiya E; Atomi Y; Ponder BA; Nakamura Y; Hamamoto R
Cancer Sci; 2011 Jul; 102(7):1298-305. PubMed ID: 21539681
[TBL] [Abstract][Full Text] [Related]
4. CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity.
Karakashev S; Zhu H; Wu S; Yokoyama Y; Bitler BG; Park PH; Lee JH; Kossenkov AV; Gaonkar KS; Yan H; Drapkin R; Conejo-Garcia JR; Speicher DW; Ordog T; Zhang R
Nat Commun; 2018 Feb; 9(1):631. PubMed ID: 29434212
[TBL] [Abstract][Full Text] [Related]
5. The Ezh2 polycomb group protein drives an aggressive phenotype in melanoma cancer stem cells and is a target of diet derived sulforaphane.
Fisher ML; Adhikary G; Grun D; Kaetzel DM; Eckert RL
Mol Carcinog; 2016 Dec; 55(12):2024-2036. PubMed ID: 26693692
[TBL] [Abstract][Full Text] [Related]
6. SAM-Competitive EZH2-Inhibitors Induce Platinum Resistance by EZH2-Independent Induction of ABC-Transporters.
Groß E; Hilger RA; Schümann FL; Bauer M; Bouska A; Rohde C; Willscher E; Lützkendorf J; Müller LP; Edemir B; Mueller T; Herling M; Binder M; Wickenhauser C; Iqbal J; Posern G; Weber T
Cancers (Basel); 2023 Jun; 15(11):. PubMed ID: 37297005
[TBL] [Abstract][Full Text] [Related]
7. HSF1 Pathway Inhibitor Clinical Candidate (CCT361814/NXP800) Developed from a Phenotypic Screen as a Potential Treatment for Refractory Ovarian Cancer and Other Malignancies.
Pasqua AE; Sharp SY; Chessum NEA; Hayes A; Pellegrino L; Tucker MJ; Miah A; Wilding B; Evans LE; Rye CS; Mok NY; Liu M; Henley AT; Gowan S; De Billy E; Te Poele R; Powers M; Eccles SA; Clarke PA; Raynaud FI; Workman P; Jones K; Cheeseman MD
J Med Chem; 2023 Apr; 66(8):5907-5936. PubMed ID: 37017629
[TBL] [Abstract][Full Text] [Related]
8. siRNA silencing EZH2 reverses cisplatin-resistance of human non-small cell lung and gastric cancer cells.
Zhou W; Wang J; Man WY; Zhang QW; Xu WG
Asian Pac J Cancer Prev; 2015; 16(6):2425-30. PubMed ID: 25824776
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of cancer stem cell markers CD133, CD44, CD24: association with AKT isoforms and radiation resistance in colon cancer cells.
Sahlberg SH; Spiegelberg D; Glimelius B; Stenerlöw B; Nestor M
PLoS One; 2014; 9(4):e94621. PubMed ID: 24760019
[TBL] [Abstract][Full Text] [Related]
10. Ovarian cancer stem cells.
Zeimet AG; Reimer D; Sopper S; Boesch M; Martowicz A; Roessler J; Wiedemair AM; Rumpold H; Untergasser G; Concin N; Hofstetter G; Muller-Holzner E; Fiegl H; Marth C; Wolf D; Pesta M; Hatina J
Neoplasma; 2012; 59(6):747-55. PubMed ID: 22862176
[TBL] [Abstract][Full Text] [Related]
11. Identification of a distinct population of CD133(+)CXCR4(+) cancer stem cells in ovarian cancer.
Cioffi M; D'Alterio C; Camerlingo R; Tirino V; Consales C; Riccio A; Ieranò C; Cecere SC; Losito NS; Greggi S; Pignata S; Pirozzi G; Scala S
Sci Rep; 2015 May; 5():10357. PubMed ID: 26020117
[TBL] [Abstract][Full Text] [Related]
12. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.
Chau WK; Ip CK; Mak AS; Lai HC; Wong AS
Oncogene; 2013 May; 32(22):2767-81. PubMed ID: 22797058
[TBL] [Abstract][Full Text] [Related]
13. Ovarian cancer stem cells are enriched in side population and aldehyde dehydrogenase bright overlapping population.
Yasuda K; Torigoe T; Morita R; Kuroda T; Takahashi A; Matsuzaki J; Kochin V; Asanuma H; Hasegawa T; Saito T; Hirohashi Y; Sato N
PLoS One; 2013; 8(8):e68187. PubMed ID: 23967051
[TBL] [Abstract][Full Text] [Related]
14. Loss of the oligosaccharyl transferase subunit TUSC3 promotes proliferation and migration of ovarian cancer cells.
Vaňhara P; Horak P; Pils D; Anees M; Petz M; Gregor W; Zeillinger R; Krainer M
Int J Oncol; 2013 Apr; 42(4):1383-9. PubMed ID: 23404293
[TBL] [Abstract][Full Text] [Related]
15. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent.
Xu K; Wu ZJ; Groner AC; He HH; Cai C; Lis RT; Wu X; Stack EC; Loda M; Liu T; Xu H; Cato L; Thornton JE; Gregory RI; Morrissey C; Vessella RL; Montironi R; Magi-Galluzzi C; Kantoff PW; Balk SP; Liu XS; Brown M
Science; 2012 Dec; 338(6113):1465-9. PubMed ID: 23239736
[TBL] [Abstract][Full Text] [Related]
16. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
McCabe MT; Ott HM; Ganji G; Korenchuk S; Thompson C; Van Aller GS; Liu Y; Graves AP; Della Pietra A; Diaz E; LaFrance LV; Mellinger M; Duquenne C; Tian X; Kruger RG; McHugh CF; Brandt M; Miller WH; Dhanak D; Verma SK; Tummino PJ; Creasy CL
Nature; 2012 Dec; 492(7427):108-12. PubMed ID: 23051747
[TBL] [Abstract][Full Text] [Related]
17. piR-1919609 Is an Ideal Potential Target for Reversing Platinum Resistance in Ovarian Cancer.
Yan Y; Tian D; Zhao B; Li Z; Huang Z; Li K; Chen X; Zhou L; Feng Y; Yang Z
Technol Cancer Res Treat; 2024; 23():15330338241249692. PubMed ID: 38706262
[TBL] [Abstract][Full Text] [Related]
18. EZH2 Contributes to Anoikis Resistance and Promotes Epithelial Ovarian Cancer Peritoneal Metastasis by Regulating m6A.
Wang SH; Liu L; Bao KY; Zhang YF; Wang WW; Du S; Jia NE; Suo S; Cai J; Guo JF; Lv G
Curr Med Sci; 2023 Aug; 43(4):794-802. PubMed ID: 37498408
[TBL] [Abstract][Full Text] [Related]
19. The Roles of Exosomes in Ovarian Cancer Chemo-resistance.
Liu Y; Li X; Zhang T; Liu G
J Cancer; 2023; 14(11):2128-2144. PubMed ID: 37497408
[TBL] [Abstract][Full Text] [Related]
20. Deciphering Common Traits of Breast and Ovarian Cancer Stem Cells and Possible Therapeutic Approaches.
Lučić I; Kurtović M; Mlinarić M; Piteša N; Čipak Gašparović A; Sabol M; Milković L
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
